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Abstract
Background and Aims: Chronic pancreatitis and pancreatic cancer are characterised by extensive stellate cell mediated
fibrosis, and current therapeutic development includes targeting pancreatic cancer stroma and tumor-host interactions.
Recent evidence has suggested that circulating bone marrow derived stem cells (BMDC) contribute to solid organs. We
aimed to define the role of circulating haematopoietic cells in the normal and diseased pancreas.
Methods: Whole bone marrow was harvested from male b-actin-EGFP donor mice and transplanted into irradiated female
recipient C57/BL6 mice. Chronic pancreatitis was induced with repeat injections of caerulein, while carcinogenesis was
induced with an intrapancreatic injection of dimethylbenzanthracene (DMBA). Phenotype of engrafted donor-derived cells
within the pancreas was assessed by immunohistochemistry, immunofluorescence and in situ hybridisation.
Results: GFP positive cells were visible in the exocrine pancreatic epithelia from 3 months post transplantation. These
exhibited acinar morphology and were positive for amylase and peanut agglutinin. Mice administered caerulein developed
chronic pancreatitis while DMBA mice exhibited precursor lesions and pancreatic cancer. No acinar cells were identified to
be donor-derived upon cessation of cerulein treatment, however rare occurrences of bone marrow-derived acinar cells were
observed during pancreatic regeneration. Increased recruitment of BMDC was observed within the desmoplastic stroma,
contributing to the activated pancreatic stellate cell (PaSC) population in both diseases. Expression of stellate cell markers
CELSR3, PBX1 and GFAP was observed in BMD cancer-associated PaSCs, however cancer-associated, but not pancreatitis-
associated BMD PaSCs, expressed the cancer PaSC specific marker CELSR3.
Conclusions: This study demonstrates that BMDC can incorporate into the pancreas and adopt the differentiated state of
the exocrine compartment. BMDC that contribute to the activated PaSC population in chronic pancreatitis and pancreatic
cancer have different phenotypes, and may play important roles in these diseases. Further, bone marrow transplantation
may provide a useful model for the study of tumor-host interactions in cancer and pancreatitis.
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Introduction
Pancreatic cancer (PC) remains one of the most devastating
cancers, and is the fourth leading cause of cancer death in western
societies with a survival rate of less than 5% [1]. Nothing apart
from pancreatic resection in a proportion of patients (10–20%),
offers any curative potential, with chemotherapeutic agents
meeting limited success [2]. Chronic pancreatitis is a significant
risk factor for the development of pancreatic cancer and both are
characterised by extensive stellate cell mediated fibrosis, which in
the case of pancreatic cancer facilitates cancer progression and
metastasis [3,4]. Recently, Olive et al [5] demonstrated that, by
targeting the stroma using inhibitors of hedgehog signalling,
significantly improves the delivery of chemotherapeutic agents to
the epithelial compartment of the tumor, and although the effect
was transient, improved overall efficacy. Further, Kraman et al
demonstrated that targeting specific sub-populations of stromal
cells for destruction could remove their inhibitory effect on the
host’s immune response to the tumor [6].
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adult stem cells have remarkable flexibility in their differentiation
repertoires. This plasticity allows adult stem cells, particularly
those of bone marrow origin, to engraft alternative non-
haematopoietic locations and transdifferentiate into cell types
appropriate to their new niche. This is particularly evident when
the recipient organ is damaged [7,8]. Bone marrow derived cells
(BMDC) can either engraft or fuse to adopt, or be reprogrammed,
to the differentiated state of the particular epithelia [9] (reviewed
in [10]). This suggests that the endogenous stem cell of an organ,
and its role in growth and regeneration, is not confined to each
specific organ but may be a dynamic system involving circulating
BMDC with stem cell niche environments regulating recruitment,
proliferation and differentiation [7,11]. This may have significant
implications concerning the evolution of cancers in many solid
organs, including the pancreas. Houghton et al demonstrated that
in a model of Helicobacter felis induced gastric carcinogenesis, the
development of metaplasia and dysplasia was linked to the
engraftment and expansion of the BMDC population, eventually
giving rise to gastric adenocarcinoma [12]. Observations in
women who received bone marrow transplants from male donors,
and who subsequently developed a cancer, identified that
myofibroblasts (pancreatic stellate cell equivalent) within these
tumors were derived from donor bone marrow [13].
The majority of previous studies assessing the role of BMDC in
pancreatic regeneration and repair have concentrated on restoring
endocrine function following islet cell injury [14,15,16,17,18,19,
20,21]. Few studies have focussed on the contribution of BMDC to
growth and regeneration of the exocrine pancreas, or their role in
pancreatic cancer. Wang et al [22] describe the contribution of
BMDC to pancreatic duct formation in neonatal mice, Marrache
et al [23], and Watanabe et al [24] demonstrate in a model of
caerulein induced chronic pancreatitis that BMDC contribute to
the pancreatic stellate cell population suggesting a role in tissue
repair, while more recently Pan et al [25] identified a contribution
of BMDC to the pancreatic stellate cell population in a rat model
of chemical carcinogenesis.
Here we generate a robust model of whole bone marrow
transplantation to show that in pancreatic carcinogenesis, and in
chronic pancreatitis, BMDC contribute significantly to the
activated pancreatic stellate cell (PaSC) population. Those
associated with pancreatic cancer express genes characteristic
of peritumoral stellate cells as compared to those not
associated with malignancy, suggesting that BMDC may play
an important role in supporting pancreatic carcinogenesis. In
addition, these models of bone marrow transplantation may prove
useful in investigating tumor-host interactions in vivo.
Methods
Ethics Statement
All animal work was approved by the Garvan Institute of
Medical Research/St Vincent’s Hospital Animal Ethics Commit-
tee (Protocol #06/53).
Bone Marrow Transplantation
Whole bone marrow was harvested from male C57/BL6-
TgN(ACTbEGFP)IOsb/J (The Jackson Laboratory, Bar Harbor,
ME, USA; hereafter referred to as the b-actin-EGFP mouse) by
flushing the tibias and femurs with Dulbecco’s Modified Eagle’s
Medium (DMEM; Invitrogen, Eugene, OR, USA) using a 26G
needle. Cells were filtered through a 70 mM cell strainer, counted,
then washed and resuspended in PBS. 5610
6 b-actin-EGFP bone
marrow cells were transplanted into irradiated (950 Rads;
Gammacell 40 Exactor; Nordion International Inc. Canada)
recipient 4–8 week old female C57/B6 mice via the tail vein. Mice
were given antibiotic water (40 mg/5 ml trimethoprim + 200 mg/
5 ml sulfamethoxazole) for 14 days. While the use of enhanced
green fluorescent protein (GFP) has become the marker of choice
for many types of cell transplantation and lineage marking
experiments, it is not clear that the GFP expressed in bone
marrow stem cells would continue to be expressed in non-
haematopoietic tissues following nuclear reprogramming
[26,27,28]. Consequently, we performed gender mismatched
transplants to track the fate of donor-derived cells using the Y
chromosome genotypic marker to validate the findings observed
using the GFP reporter.
Normal Pancreas
Mice were sacrificed at 3 (n=12), 6 (n=12), 9 (n=12) and 12
(n=11) months post transplantation (Figure 1). At each time point,
the pancreas was harvested, halved and placed in either 10%
neutral buffered formalin then embedded in paraffin, or embedded
in cold Tissue-Tek OCT Compound (Sakura Finetek, Torrance,
CA, USA) and snap frozen in liquid N2. Cellular phenotype of
donor derived cells within the pancreas were assessed by
immunohistochemistry, immunofluorescence and in situ hybridisa-
tion for the Y chromosome. To monitor engraftment of donor b-
actin-EGFP bone marrow, peripheral blood was assessed for GFP
positivity using Fluorescence Activated Cell Sorting (FACS) at 1
month post transplantation, then upon sacrifice (Table 1).
Chronic Pancreatitis
One month after transplantation, mice were injected intraper-
itoneally with 50 mg/kg of caerulein (#152860; MP Biomedicals
Inc., Solon, OH, USA) 5 times over 4 consecutive hours, twice a
week for 10 weeks as previously described [29]. Mice were
sacrificed upon completion of caerulein treatment (n=8) and 3
(n=8), 6 (n=8) and 9 (n=8) months post caerulein treatment to
assess pancreatic regeneration. An additional arm assessed
pancreatic regeneration in mice treated with caerulein at 6
months post transplantation and sacrificed at 3 months post
cessation of caerulein treatment (n=4) (Figure 1).
Chemical Model of Pancreatic Cancer
One month after transplantation, mice were anaesthetised with
isofluorane and a left lateralsubcostal incision inthe abdominal wall
was performed and the spleen exteriorised to reveal the body and
tail of the pancreas. 1 mg/50 ml of 7,12-dimethylbenzanthracene
(DMBA; Sigma-Aldrich, St Louis, MO, USA) was dissolved in
PBS/0.1% TWEEN and injected into the tail of the pancreas using
a 25G needle as previously described [30]. The spleen and pancreas
were returned to the abdominal cavity and the peritoneum/muscle
layers and skin were sutured closed. Mice were sacrificed between
1–4 (n=16), 5–8 (n=6), 9–12 (n=4) and .12 (n=2) weeks post
DMBA treatment orwhen a pancreatic mass wasdetected following
abdominal palpation (Figure 1). As with the model of chronic
pancreatitis, an additional arm assessed the contribution of BMDC
to pancreatic carcinogenesis following induction with DMBA at
both 6 (n=10) and 9 (n=10) months post transplant.
FACS analysis
Peripheral blood and bone marrow cells were analysed for GFP
expression using fluorescence-activated cell sorting (FACS)
(Table 1).
Peripheral Blood. At 1 month post transplantation and
upon sacrifice, blood was collected via tail bleed and collected in
BMDC and Pancreatic Cancer
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USA). 1000 ml FACSlyse (1X) was then added and incubated for
10 minutes at room temperature. The tubes were centrifuged at
1000 g for 5 mins, the supernatant removed and the cells
resuspended in 200 ml of cold PBS on ice until analysis.
Bone Marrow. Bone marrow was flushed from the femurs of
transplanted mice with cold PBS using a 26G needle, filtered
through a 70 mM cell strainer and held on ice until analysis.
Fluorescence-activated cell sorting (FACS) analysis was carried out
using a BD FACS CANTO (BD, Franklin Lakes, NJ, USA).
Immunohistochemistry/Immunofluorescence/In-situ
hybridisation
Immunohistochemistry. Paraffin embedded pancreatic
tissue sections (4 mm) were de-waxed and rehydrated before
H&E staining to assess histological morphology. For
immunohistochemistry, antigen unmasking was achieved using
target-retrieval solution (s2367, pH 9.0: DAKO Corporation,
Carpenteria, California, USA) for 30 minutes in a boiling water
bath. Endogenous peroxidase activity was quenched with 3%
hydrogen peroxide (5 minutes), rinsed in DAKO buffer (DAKO
Corporation) then slides were blocked with DAKO Protein block
(10 minutes; DAKO Corporation). Sections were then incubated
for 60 minutes with primary antibody (see below) then a labelled
polymer horseradish peroxidase anti-rabbit detection system was
used (30 minutes; Envision+ anti-rabbit; DAKO Corporation) and
3,39-diaminobenzidine was used as a substrate. Counter-staining
was performed with Mayer’s hematoxylin (DAKO Corporation).
Immunofluorescence. For immunofluorescence analysis,
4 mm paraffin sections were de-waxed, rehydrated and antigen
retrieved as described above. Sections were then blocked with
Protein block (10 minutes), then primary antibodies (see below)
were incubated for 1 hour at room temperature, washed in
DAKO buffer (365 minutes) and incubated in secondary
antibodies (see below) for 1 hour at room temperature.
Fluorescent staining of apical membranes of exocrine acinar cells
was performed using rhodamine-conjugated peanut agglutinin
(PNA; 1:200; Vector Laboratories, Burlingame, CA, USA). The
slides were rinsed then counterstained and mounted in Vectashield
hard set mounting medium with DAPI (H-1500; Vector
Laboratories).
Primary Antibodies: GFP rabbit polyclonal (A11122; Invitro-
gen, Eugene, OR, USA; 1:1000 IHC, 1:200 IF), GFP goat
polyclonal (ab5450; Abcam, Cambridge, MA, USA; 1:1000),
amylase goat polyclonal (C-20; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA; 1:200 IF), desmin (Thermo Scientific,
Table 1. Assessment of engraftment of donor derived cells in
peripheral blood and bone marrow.
% GFP Positive Cells (95% CI)
Months post transplant Peripheral Blood Bone Marrow
1 81.92 (80.71-83.10) ---
3 76.26 (71.89-80.37) 25.39 (23.32-27.52)
6 86.80 (82.77-90.37) 22.26 (19.63-25.01)
9 73.81 (68.42-78.85) 22.77 (20.26-25.39)
12 83.68 (78.56-88.21) 27.54 (24.83-30.34)
doi:10.1371/journal.pone.0026088.t001
Figure 1. Experimental overview. 5610
6 bone marrow cells from male b-actin-EGFP mice were transplanted into lethally irradiated female C57/
B6 mice. For assessment of the normal pancreas, pancreata were harvested at 3, 6, 9 and 12 months post transplant. For chronic pancreatitis, mice
were administered caerulein intraperitoneally for 10 weeks then sacrificed upon cessation of the treatment, as well as 3, 6 and 9 months post
treatment to assess regeneration. For pancreatic cancer, at 1 month post transplant mice were administered an intrapancreatic injection of 7,12-
dimethylbenzanthracene (DMBA) and sacrificed by 4, 8, 12 or .12 months post DMBA treatment or when a pancreatic mass was detected.
doi:10.1371/journal.pone.0026088.g001
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monoclonal (clone 1A4; A5228; Sigma-Aldrich, St Louis, MO,
USA; 1: 1:500 IHC/IF), Vimentin (SP-20; Epitomics, Burlingame,
CA, USA; 1:200 IHC), Cytokeratin 5/6 (D-13; Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA; 1:100 IHC), glial
fibrillary acidic protein (GFAP) rabbit polyclonal (Z0334; DAKO
Corporation, Carpenteria, California, USA; 1:50), pre-B-cell
leukemia transcription factor 1 (PBX1) rabbit polyclonal
(ab12001; Abcam, Cambridge, MA, USA; 1:100), cadherin EGF
LAG seven-pass G-type receptor 3 (CELSR3) rabbit polyclonal
(ab12958; Abcam, Cambridge, MA, USA; 1:100).
Secondary Antibodies: anti-rabbit Cy5 (1:250; #711-176-152;
Jackson ImmunoResearch, West Grove, PA, USA), anti-goat Cy5
(1:250; #705-175-003; Jackson ImmunoResearch, West Grove,
PA, USA), anti-goat Cy3 (1:500; #715-166-147; Jackson Im-
munoResearch), anti-mouse Cy3 (1:500; #715-166-150; Jackson
ImmunoResearch).
In-situ hybridization. Whole mouse Y chromosome probe
labelled with fluorescein (Star*FISH, #1189-YMF-01; Cambio Ltd)
was applied to 3 um paraffin sections following deparaffinization in
xylene, pre-treatment with DAKO target retrieval solution (TRS:
30 mins at 95uC), protease digestion at 37uC for 15 minutes and
post-fixation in neutral buffered formalin for 10 mins. Hybridization
site was selected by reference to a serial section stained with H+E.
3.5 mL probe was applied under a 15615 mm coverslip sealed with
rubber cement. Co-denaturation at 90uC was followed by overnight
hybridization at 37uC on a thermal cycler block. After post
hybridization rinses in 2X SSC/0.3% NP-40 (262m i n sa t7 2 uC),
slidesweredried and counterstained with DAPI.Signalwas analysed
with a Zeiss Axioscope II microscope with digital AxioCam and
AxioVision software.
Results
Successful reconstitution of bone marrow in transplanted mice
was demonstrable in peripheral blood at 1 month post transplant
using FACS analysis for GFP expression. In addition, long term
engraftment was verified at the time of sacrifice. GFP positivity of
peripheral blood and bone marrow at each timepoint was
comparable to that of the donor b-actin-EGFP mouse (Blood,
70.07%63.90 SEM; Marrow, 30.87%61.60 SEM) (Table 1).
BMDC and normal exocrine pancreas
From 3 months post transplantation, individual, donor-derived
GFP positive cells were seen within the exocrine pancreatic
epithelial compartment of non-treated control transplanted mice
(Figure 2A). Small GFP positive cells that had spindle-like, or
immune cell morphology were scattered throughout the interstitium
Figure 2. Normal pancreas in bone marrow transplant recipients. GFP immunohistochemistry of pancreata identified individual GFP+ve
donor-derived cells with acinar cell morphology from 3 months post transplantation (A), and occasional entire acinar units (B), were observed from 6
months post transplantation. Immunofluorescence images of donor derived GFP+ve acinar cells co-staining positive for both GFP and amylase (C, E);
and GFP and PNA (D, F).
doi:10.1371/journal.pone.0026088.g002
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acinar morphology were present in the exocrine compartment.
Uponfurtherexaminationusingco-immunofluorescence,thesecells
were positive for GFP, amylase and peanut agglutinin (Figure 2C,
2D), markers specific for pancreatic acinar cells, suggesting that
BMDC can incorporate into the adult pancreas and adopt the
differentiated state of the exocrine compartment. Cohesive clusters
of 2–3 cells were observed from 6 months post transplantation,
while occasional entire acinar unitsconsistingofdonor-derived GFP
positive cells were also evident (Figure 2B, 2E, 2F).
BMDC and pancreatic injury
An experimental arm to assess engraftment of donor BMDC in
pancreas specific injury (chronic pancreatitis) and regeneration was
also established. Following 10 weeks of caerulein treatment, mice
had pancreata that had atrophied, and peri-acinar fibrosis
developed as a fine meshwork throughout the exocrine gland.
Intra-acinar lumina were dilated. Some acinar units appeared to
develop a ductal phenotypewith loss ofzymogen granules and more
centrally located nuclei. These tubular complexes consisted of
cylinders with a wide lumen lined by a monolayer of flattened duct-
like cells (Figures S1B, E) [31,32]. Control pancreata were
histologically normal (Figure S1A). Sirius red staining of interstitial
collagen was more prominent in the caerulein treated mice,
indicative of chronic injury. Staining in control animals was
localised primarily around ducts, small blood vessels with thin
strandsextendingbetweenlarger lobules, and not aroundindividual
acinar units. In the caerulein treated animals periacinar collagen
increased, surrounding individual acinar units, similar to the fibrosis
observed in human chronic pancreatitis (Figures S1D, E).
Upon cessation of caerulein treatment (3 months post
transplantation immediately following injury) there was increased
BMDC recruitment to the pancreas (Figure 3A). This included
recruitment of GFP positive inflammatory cells such as lympho-
cytes (positive for CD45 expression; data not shown) and
macrophages, while some BMDC located interstitially were
positive for desmin, and spindle-like peri-acinar cells possessed
the morphology of pancreatic stellate cells (PaSC’s; Figure 3C). No
acinar cells were identified to be donor derived (GFP positive) at
this early timepoint.
BMDC and pancreatic regeneration
Upon cessation of caerulein treatment, animals were left to
recover to assess the contribution of BMDC to pancreatic
regeneration. Following 3 months of recovery post cessation of
caerulein treatment, pancreata of treated animals returned to a
histologically normal phenotype (Figure S1C), resembling that of
non-treated animals. A reduction of interstitial and periacinar
collagen was also visible (Figure S1F). As for normal pancreas, only
rare occurrences of single and small clusters of GFP positive acinar
cells displaying amylase and PNA positivity were observed,
suggesting that BMDC could adopt the differentiated state of
the exocrine compartment during pancreatic regeneration.
Interstitial GFP positive inflammatory cells were diminished in
number as regeneration time increased (Figure 3B). Similar results
were observed for mice that were treated with caerulein following
long term engraftment (6 months post transplant) and left to
recover. In situ hybridisation for the Y chromosome confirmed that
there was no increase in the contribution of BMDC to the
exocrine pancreas with regeneration (Figure 3D).
BMDC and pancreatic cancer
Two weeks after injection of DMBA, tubular complexes were
present focally among acinar cells with ductal metaplasia adjacent
Figure 3. GFP immunohistochemistry of caerulein treated transplanted mice upon cessation of treatment to assess BMDC
contribution to pancreatic injury (A), and following 6 months of recovery to assess pancreatic regeneration (B). Note the increased
presence of GFP positive cells within the interstitium of the injured pancreas, including inflammatory infiltrate (A), when compared to the
regenerated pancreas (B); as well as the GFP positive spindle-like cells (black arrows) with a pancreatic stellate cell morphology (C) surrounding acinar
units (a); (D) Y chromosome FISH confirmed the minimal contribution of BMDC to the regeneration of exocrine parenchyma, while some Y positive
lymphocytes were observed throughout the parenchyma (white arrows).
doi:10.1371/journal.pone.0026088.g003
BMDC and Pancreatic Cancer
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DMBA treatment, pancreatic precursor lesions (mPanIN) with
varying degrees of dysplasia were present. Foci of adenocarcinoma
in relation to mPanIN were seen in the pancreas from 2 months
after DMBA, while ductal adenocarcinoma (sarcomatoid variant)
developed at 3–4 months (Figures S1G-I). This phenotype closely
resembled that seen in a similar model used by Kimura et al [30].
We assessed the contribution of BMDC to the desmoplastic
stroma, in particular to the population of pancreatic stellate cells,
by assessing co-expression of GFP and the stellate cell selective
markers desmin, glial fibrillary acidic protein (GFAP), a-smooth
muscle actin (aSMA), the co-expression of which defines activated
stellate cells [3,33,34] (reviewed in [35]). These markers, originally
identified as PaSC specific, are used to distinguish PaSC’s from
normal fibroblasts due to the co-expression of the intermediate
filament proteins desmin and GFAP [33,34], while expression of
aSMA in PaSC’s was originally described as a source of fibrosis in
chronic pancreatitis and pancreatic cancer, designating activated
PaSC’s [3,36]. There was significant BMDC recruitment to the
stroma surrounding precursor lesions following DMBA treatment,
with contribution of BMDC to the activated pancreatic stellate cell
population (GFP, desmin and aSMA positive; Figure S2A,C,E).
Co-immunofluorescence analysis also demonstrated that donor-
derived BMDC positive for both GFP and aSMA was present in
cells directly adjacent to pancreatic intraepithelial neoplasia
(mPanIN) lesions (Figure S2B,D,F). We also observed the
development of a large, poorly differentiated and invasive
cytokeratin positive/vimentin negative ductal adenocarcinoma
(sarcomatoid) tumor with a significant BMDC population
(Figure 4A, 4B), which included an extensive donor derived
inflammatory infiltrate, demonstrated using FISH for the Y-
chromosome (Y-FISH; Figure 4C), as well as bone marrow
derived activated pancreatic stellate cells (Figure 4D), visualized by
co-immunofluorescence of GFP with aSMA (Figure 4D). Bone
marrow derived epithelial tumor cells were not seen. We
quantified the proportion of BMDC within the tumor microen-
vironment in 5 high power magnification fields (400X) and
determined that 41.8% (6 2.77 SEM) of cells were bone marrow
derived (Figure 4). Similar results were observed when we
administered DMBA following long term engraftment (6 months
post transplant).
More recently, Erkan et al [37] used transcript profiling to
identify markers to differentiate PaSC’s associated with chronic
pancreatitis versus those of pancreatic cancer, with the aim of
subtyping PaSC’s into either inflammation or cancer-associated.
Pre-B-cell leukemia transcription factor 1 (PBX1) was upregulated
in inflammation-associated PaSC’s compared to tumor-associated
PaSC’s, while cadherin EGF LAG seven-pass G-type receptor 3
(CELSR3) expression was upregulated in tumor-associated PaSC’s
compared to that of inflammation-associated PaSC’s [37]. We
examined 5 sections each from 3 mice that developed adenocar-
cinoma and observed that GFAP, PBX1 and CELSR3 expression
was co-localised with GFP in tumor associated PaSC’s (Figure
S3A, S3B, S3C respectively), and although PBX1 (but not
CELSR3) was detected in the stroma in pancreatitis, it did not
co-localise with GFAP, suggesting that it was not expressed in
activated stellate cells.
Discussion
Gender-mismatched whole bone marrow transplants demon-
strated that BMDC migrate to the pancreas and expand as clonal
units to adopt differentiated states of the exocrine compartment.
Although there was minimal recruitment to the acinar cell
population, which did not increase with injury, regeneration, or
carcinogenesis, there was significant recruitment to the stroma.
Although the majority of recruited cells during acute injury and
cancer were inflammatory cells, a proportion differentiated into
stellate cells. Those associated with cancer expressed markers
characteristic of tumor-associated stellate cells suggesting they
were co-opted, and altered by the tumor microenvironment.
Whilst regenerative capacity is maintained in the adult exocrine
pancreas, the origin of regenerating epithelium remains unclear
[38]. Recently, a mechanism of clonal development of pancreatic
Figure 4. Assessment of the sarcomatoid-like tumor following treatment with DMBA. (A) H&E showing the poorly differentiated, invasive
pancreatic tumor; (B) GFP IHC and (C) Y chromosome FISH, demonstrate the extensive bone marrow derived cell population within the tumor; (D) Co-
immunofluorescence of GFP with aSMA identified bone marrow derived activated stellate cells within the tumor (arrowhead).
doi:10.1371/journal.pone.0026088.g004
BMDC and Pancreatic Cancer
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progenitor cell, whether it be a mature acinar cell or a multipotent
stem cell, gives rise to all exocrine cells of one acinus [39]. Further,
lineage tracing studies provide evidence that new acinar cells are
generated from pre-existing acinar cells following partial pancrea-
tectomy [40] and caerulein induced pancreatitis [41]. Given these
data, and our observations in the normal pancreas, we hypothesized
that BMDCs contribute to the regeneration of the exocrine
compartment. Despite using different injury protocol time-points
we were unable to demonstrate a significant increase in the BMDC
contribution to the acinar cell population. Y chromosome FISH
data excluded GFP silencing [42,43,44] as a potential cause for lack
of GFP expression, and reflected GFP positive cell distribution.
PaSC’s are resident myofibroblast-like cells existing in the
periacinar space of the exocrine pancreas, and there is increasing
evidencetosuggestthattheyarekeyparticipantsinthepathogenesis
of pancreatic exocrine diseases, particularly in the production of
abundantfibrousstroma,whichisafeatureofpancreaticcancer[3].
Although there was significant BMDC recruitment to the
inflammatory infiltrate at the time of pancreatic injury consistent
with previous reports [45,46], this was transient and cell numbers
diminished over time to low levels when regeneration was complete.
However, stellate cells remained amongst the residual population of
BMDC. This observation suggests that BMDC play a role in
supporting the regenerative process, but do not transform to
contribute to the regenerative epithelium itself. Tumor associated
BMDC PaSC’s may be retained in the peri-tumoral stroma, whilst
those associated with pancreatitis are not. Although the number of
bone marrow derived PaSC was slightly less in the setting of
pancreatitis compared to cancer, longer timepoints would be
required to determine if BMDC were preferentially retained in the
pancreas in the setting of cancer.
As in chronic pancreatitis, there was increased recruitment of
BMDC to the pancreas following treatment with DMBA. This
again included an inflammatory infiltrate and activated PaSC’s.
Importantly, expression of CELSR3 in BMDC associated with
tumor suggests that there was modification of these PaSC’s by the
tumor microenvironment. This is supported by recent studies where
bone marrow-derived mesenchymal stem cells preferentially localise
to regions of pancreatic tumor growth [47] and have been shown to
transform into tumor-associated myofibroblasts in insulinomas [48].
Pancreatic cancer cells secrete growth factors such as TGF-b1,
PDGF and VEGF, as well as extracellular matrix (ECM)
metalloproteinase inducers that transform the usually quiescent
PaSC’s into an activated myofibroblast-type phenotype and secrete
excess amounts of ECM and matrix degrading enzymes [3,4,49]
(reviewed in [50]). Vonlaufen and colleagues [51] provide evidence
of a bi-directional interaction between tumor cells and pancreatic
stellate cells. In addition, orthotopic xenograft models of pancreatic
cancer demonstrate that tumors consisting of a mix of tumor cells
and PaSC’s are larger and exhibit distant regional metastases, with
activated PaSC’s present within the metastases [51]. The impor-
tance of specific stromal cells in tumorigenesis was further defined
through a recent study by Kraman et al [6], who demonstrated that
a sub-population of stromal cells that express fibroblast activation
protein (FAP) suppress the immune response and that abrogation of
FAP expression arrests the growth of pancreatic tumors, potentially
by removing their inhibitory effect on the host’s immune response.
As a consequence, solid tumor stromal cells, such as PaSC’s, present
a potential novel therapeutic target [6,52]. In addition, the presence
of activated BMDC PaSC’s associated with mPanIN lesions suggest
that this process occurs early in pancreatic carcinogenesis.
In conclusion, whilst most cancer associated activated PaSC’s are
thought to arise from endogenous quiescent PaSC’s, we provide
evidence that a proportion of these are bone marrow derived, and
display different phenotypes depending on whether they arerecruited
to an inflammatory or a carcinogenic pancreas. Based on evidence
identifying cross-talk between pancreatic tumor cells and PaSC’s
[51], our data suggest that bone marrow-derived PaSC’s may play an
important, and supportive role in promoting carcinogenesis, the
mechanisms of which remain to be elucidated. In addition, these
models can potentially be used to selectively manipulate the genetic
composition of PaSC’s, to facilitate the in vivo investigation of tumor-
host interaction, where such models have not previously existed.
Supporting Information
Figure S1 Representative images of the pancreata from control
(A, D), caerulein (B–C, E–F) and DMBA treated mice (G–I).
Control pancreata were histologically normal, with tightly packed
acinar units (A), and interstitial collagen localised primarily around
ducts and between large lobules (A, D; arrow). Treatment with
caerulein revealed dilated intra-acinar lumina (L) the development
of a ductal-like phenotype, presenting as tubular complexes (T),
and periacinar fibrosis with increased inflammatory infiltrate (H &
B). Sirius red staining revealed increased interstitial (arrow) and
periacinar (arrowhead) collagen (E). Following 3 months of
recovery post cessation of caerulein, the pancreata returned to a
histologically normal phenotype (C) with reduction of interstitial
(arrow) and periacinar collagen (F). Treatment with DMBA
resulted in the development of mPanIN lesions (*) and pancreatic
cancer, which were predominantly mPanIN-1A (G), mPanIN-1B
(H), through to the sarcomatoid-like ductal adenocarcinoma (I).
(TIF)
Figure S2 Immunohistochemical and immunofluores-
cent analysis of the desmoplastic stroma following
transplantation and DMBA treatment. Serial sections
demonstrate positive co-immunohistochemical staining for GFP
(A), desmin (C) and aSMA (E). Boxes outline the same individual
cells across the serial sections. Co-immunofluorescence for GFP (B)
and aSMA (D) showing a bone marrow derived activated
pancreatic stellate cell in the stroma directly adjacent to the
PanIN lesion.
(TIF)
Figure S3 Immunofluorescent characterisation of the
bone marrow derived stellate cells within the sarcoma-
toid-like tumor following treatment with DMBA. Co-
immunofluorescence of GFP with (A) glial fibrillary acidic protein
(GFAP), (B) pre-B-cell leukemia transcription factor 1 (PBX1), and
(C) cadherin EGF LAG seven-pass G-type receptor 3 (CELSR3) to
identify bone marrow derived activated stellate cells within the
tumor (arrowhead).
(TIF)
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